<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843605</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC21.0036</org_study_id>
    <nct_id>NCT04843605</nct_id>
  </id_info>
  <brief_title>Systematic Screening for COPD in Tabacology Consultation</brief_title>
  <acronym>DEBOTA</acronym>
  <official_title>Impact of Systematic Screening for COPD in Tabacology Consultation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD is a very common disease, an estimated 3 million people are affected in France.&#xD;
      Unfortunately, this pathology is under-diagnosed. Several reasons can be mentioned: the&#xD;
      banality of the symptoms or the several comorbidities.&#xD;
&#xD;
      Screening faces a major difficulty: the realization of a spirometry. Various studies have&#xD;
      shown the complexity of the implementation of mass screening in cities by mini-spirometry.&#xD;
&#xD;
      The COPD World Health Days allow this mass screening but without visibility on the actual&#xD;
      entry into a care pathway.&#xD;
&#xD;
      The objective of this study is to assess the impact of systematic screening for COPD during a&#xD;
      tabacology consultation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 16, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COPD DIAGNOSIS</measure>
    <time_frame>one day</time_frame>
    <description>The COPD diagnosis is preformed using a spirometry</description>
  </primary_outcome>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Smoking Cessation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients followed in tabacology unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects over 45 years old, followed in Tabacology unit at CHRU of BREST - No COPD&#xD;
             patient or COPD patients not followed for more than 3 years (considered out of care)&#xD;
&#xD;
          -  No opposition filed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already followed for COPD&#xD;
&#xD;
          -  Contraindication to spirometry&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc Beaumont, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH des pays de Morlaix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Beaumont</last_name>
    <phone>0298626160</phone>
    <email>mbeaumont@ch-morlaix.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Nicol</last_name>
    <phone>0298626160</phone>
    <email>marianne.nicol@chu-brest.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006 Jan;27(1):188-207. Review.</citation>
    <PMID>16387952</PMID>
  </reference>
  <results_reference>
    <citation>Fuhrman C, Delmas MC; pour le groupe épidémiologie et recherche clinique de la SPLF. [Epidemiology of chronic obstructive pulmonary disease in France]. Rev Mal Respir. 2010 Feb;27(2):160-8. doi: 10.1016/j.rmr.2009.08.003. Epub 2010 Jan 19. French.</citation>
    <PMID>20206064</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

